ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1037

Anti-MDA5 Antibody Associated Myositis Compared to DM Patient: A Distinct Muscular Pattern Associated with a shared  IFN Signature

Yves Allenbach1,2,3, Gaelle Leroux4, Aude Rigolet2, Baptiste Hervier5, Nicolas Limal6, Peter Hufnagl7, Norman Zerbe8, Thierry Maisonobe9, Alain Meyer10, Yurdagul Uzunhan11, Kuberaka Mariampillai12, Romain Gherardi13, Serge Herson12, Olivier Benveniste2,3 and Werner Stenzel14, 1Neuropathology, Charite Hospital, Berlin, Germany, 2Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, 3UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, 4Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, 5Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, PARIS, France, 6Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, 7Pathology departmen, Charite Hospital, Berlin, Germany, 8Department of Pathology, Charite Hospital, Berlin, Germany, 9Neuropathology, Pitie-Salpetriere Hospital, Paris, France, 10Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, 11Pneumology, APHP Avicenne Hospital, Bobigny, France, 12Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, 13Pathology, APHP Henri Mondor Hospital, Creteil, France, 14Department of Neuropathology, Charite Hospital, Berlin, Germany

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: autoantibodies, dermatomyositis and interferons

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Anti-MDA5 auto-antibodies are thought to be specifically associated with dermatomyositis (DM). Nevertheless anti-MDA5 auto-antibody positive patients (MDA5+ DM) predominantly suffer from extra-muscular involvement with severe interstitial lung disease, and arthritis. Further, skin lesions may be atypical with skin ulcers and mechanics’ hands. Importantly, clinical signs of myopathy are rather mild or absent and morphology and immunology of skeletal muscle tissue has not been studied yet. Thus, the previously described characteristic ‘IFN signature’ in classical DM may not be found in MDA5+ DM patients. We aim to describe the histological pattern of the skeletal muscle and the intrinsic immune response  MDA5+ DM patients.

Methods

Muscle specimens were subjected to conventional staining and immunohistochemical analysis to describe muscle fibers, vessel morphology and inflammatory features. Morphometry of vessels was performed using imageJ software on digitally completely scanned slides and by electron microscopy. A panel of six interferon stimulated genes (ISGs) (OAS1, OAS3, ISG15, MX1, RIG1 and MDA5), involved in the IFN immune response were tested by quantitative PCR in muscle biopsie (results expressed as normalized fold change relative to a normal muscle). The median fold change of the six ISGs, was used to create an IFN score. Results are compared to anti-MDA5 auto-antibody negative DM patients (based on ENMC criteria). Serum level of IFN-α was tested using a bioassay.

Results

In MDA5+ DM patients (n=9) the mean MRC-score (five score) of the weakest muscular group was 4.5±0.5 and CK levels were 498±809 IU/l.  Muscle biopsies (n=10) were analyzed compared to MDA5– DM patients (n=7).  Histological analysis showed that anti-MDA5+ patients did not present the classical feature of perifascicular fiber atrophy. Inflammation was focal in the perimysium and mainly perivascular but significantly less intense as it is shown by density scores of CD45+ leukocytes (35.8±28 vs. 5.9±7.6 cells/mm², p<0.05). MHC-class I staining was also less intense and more focal compared to MDA5– DM patients who harboured a diffuse staining pattern with a perifascicular re-inforcement. MDA5+  DM patients did not show signs of capillary loss since the capillary density was 279.9±17.7/mm² vs. 340.9±16.5/mm² (p=0.05) in MDA5– DM patients. In the same line the frequency of enlarged capillaries (diameter >10µm) was decreased 5.8±1.1% vs. 13.9±2.5%. Tubulo-reticular formations were observed in only 50% of MDA5+ patients, but in all cDM patients. In MDA5+ DM patients a strong up-regulation of ISGs expression was observed with RQ values ranging from 74.5±17.2 for RIG to 1107±406 for ISG15even though, the IFN score was less increased than in controls (139.5 vs 634; p=0.005). Finally IFN-α serum levels were increased in all active MDA5+DM patients (n=2). 

Conclusion

These results show that myositis in patients with anti-MDA5 Ab positivity shows a distinct morphological pattern compared to MDA5– DM patients, but is associated with an IFN signature as well, underlining the importance of this pathway in the pathogenesis of both entities.


Disclosure:

Y. Allenbach,
None;

G. Leroux,
None;

A. Rigolet,
None;

B. Hervier,
None;

N. Limal,
None;

P. Hufnagl,
None;

N. Zerbe,
None;

T. Maisonobe,
None;

A. Meyer,
None;

Y. Uzunhan,
None;

K. Mariampillai,
None;

R. Gherardi,
None;

S. Herson,
None;

O. Benveniste,
None;

W. Stenzel,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-mda5-antibody-associated-myositis-compared-to-dm-patient-a-distinct-muscular-pattern-associated-with-a-shared-ifn-signature/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology